Trinity Biotech (TRIB) investor relations material

Executive summary

• Revenue increased to $10.8m in Q1 2026 from $7.6m in Q1 2025, primarily due to significant growth in Rapid HIV sales.

• Net loss narrowed to $4.4m from $8.8m year-over-year, reflecting improved gross margin, reduced operating expenses, and lower net financing expense.

• Adjusted EBITDA loss improved to $1.1m from $4.0m loss in Q1 2025, driven by higher sales, better margins, and cost reductions.

• Received orders for over 2 million TrinScreen HIV tests, to be fulfilled in Q3 2026, supporting revenue and profitability targets.

• Demand for rapid HIV diagnostics rebounded after 2025 disruptions in international aid funding.

Financial highlights

• Gross profit rose to $3.8m from $1.9m, with gross margin improving to 35.4% from 25.2% year-over-year.

• Basic and diluted loss per ADS was $0.23, compared to $0.48 in Q1 2025.

• R&D expense was $0.9m, with $2.0m capitalized, including $1.6m for the CGM program.

• SG&A expense decreased to $4.7m from $5.5m, mainly due to salary and share-based compensation reductions.

• Net financing expense decreased to $1.8m from $2.3m, aided by a $1.5m gain on derivative remeasurement.

Outlook and guidance

• Transition to outsourced HIV production is expected to cause revenue and profitability variability between Q2 and Q3 2026.

• Commercial scale-up of outsourced manufacturing is anticipated to be substantially in place during Q3 2026.

• Orders and manufacturing scale-up reinforce confidence in achieving 2026 revenue and profitability goals.

• Continued focus on innovation and new product development to support long-term growth.